| Title |
Publication Date |
Price |
Relevance |
Boehringer Ingelheim
|
July 2008 |
£510 |
100 % |
Boehringer Ingelheim
Pipeline ,Products ,Performance ,Potential
|
November 2008 |
£595 |
100 % |
Boehringer Ingelheim GmbH Deals
Partneringdesk briefing
|
July 2005 |
£215 |
97 % |
Boehringer Ingelheim IMS Company Profile
|
November 2008 |
£510 |
97 % |
Boehringer Ingelheim IMS Company Profiles
|
June 2009 |
£510 |
97 % |
Partnering Agreements with Boehringer Ingelheim 2010
|
January 2010 |
£295 |
96 % |
Nippon Boehringer Ingelheim Co., Ltd.-Company Report
|
January 2010 |
£495 |
96 % |
Boehringer Ingelheim GmbH -Company Report
|
February 2008 |
£250 |
96 % |
Boehringer Ingelheim GmbH-Company Report
|
January 2010 |
£495 |
96 % |
Boehringer Ingelheim GmbH: PharmaVitae Profile
|
March 2009 |
£1990 |
96 % |
Boehringer Ingelheim GmbH Strategic Analysis Profile
|
November 1999 |
£520 |
95 % |
Boehringer Ingelheim: Pipeline, Products, Performance, Potential
|
April 2008 |
£595 |
95 % |
Boehringer Ingelheim GmbH - Strategic Analysis Review
|
June 2009 |
£83 |
95 % |
Boehringer Ingelheim GmbH Healthcare - Medical Equipment SWOT Report
|
August 2008 |
£83 |
93 % |
Boehringer Ingelhgeim GmbH: PharmaVitae Model
|
January 2009 |
£1990 |
36.5 % |
Boehringer Ingelheim GmbH - SWOT Analysis
|
June 2008 |
£44 |
35 % |
Flomax Case Study
Evolving Disease State Awareness to Succeed with New Method of Action
|
July 2008 |
£2110 |
22.5 % |
Chronic Obstructive Pulmonary Disease
|
February 2010 |
£2280 |
22 % |
Boehringer Ingelheim Gmbh
Pharmavitae Profile
|
December 2007 |
£1990 |
20.3 % |
Anti-Infectives
|
February 2010 |
£2610 |
19 % |
Sirolimus
Pipeline Developer
|
Ongoing |
£4435 |
19 % |
Fluticasone
Pipeline Developer
|
Ongoing |
£3450 |
19 % |
Desvenlafaxine
Pipeline Developer
|
Ongoing |
£3000 |
19 % |
Quetiapine
Pipeline Developer
|
Ongoing |
£3000 |
19 % |
Lacidipine: Core Country Coverage
Pipeline Selector
|
Ongoing |
£270 |
18.5 % |
Pramipexole: Core Country Coverage
Pipeline Selector
|
Ongoing |
£270 |
18.5 % |
Meloxicam (Vet): Core Country Coverage
Pipeline Selector
|
Ongoing |
£270 |
18.5 % |
Telmisartan: Core Country Coverage
Pipeline Selector
|
Ongoing |
£270 |
18.5 % |
Pramipexole: Extended Country Coverage
Pipeline Selector
|
Ongoing |
£625 |
18.5 % |
Telmisartan: Extended Country Coverage
Pipeline Selector
|
Ongoing |
£625 |
18.5 % |
Trandolapril
Pipeline Developer
|
Ongoing |
£2555 |
18.5 % |
Lacidipine: Extended Country Coverage
Pipeline Selector
|
Ongoing |
£625 |
18.5 % |
Meloxicam (Vet): Extended Country Coverage
Pipeline Selector
|
Ongoing |
£625 |
18.5 % |
Pyriproxyfen (Vet)
Pipeline Developer
|
Ongoing |
£2555 |
18.5 % |
Meloxicam: Core Country Coverage
Pipeline Selector
|
Ongoing |
£270 |
18 % |
Tamsulosin: Core Country Coverage
Pipeline Selector
|
Ongoing |
£270 |
18 % |
Tamsulosin: Extended Country Coverage
Pipeline Selector
|
Ongoing |
£625 |
18 % |
Meloxicam: Extended Country Coverage
Pipeline Selector
|
Ongoing |
£625 |
18 % |
Tiotropium Bromide: Extended Country Coverage
Pipeline Selector
|
Ongoing |
£625 |
18 % |
Tiotropium Bromide: Core Country Coverage
Pipeline Selector
|
Ongoing |
£270 |
18 % |
Gadopentetic acid
Pipeline Developer
|
Ongoing |
£3450 |
18 % |
Prescription Drugs
|
July 2009 |
£2610 |
15.5 % |
MorphoSys Ag
Premium Company Profile
|
April 2008 |
£175 |
15 % |
Educating the Market: Creating Value Through Support of Continuing Medical Education
|
March 2008 |
£2290 |
14.5 % |
World Veterinary Health Products
(Animal Pharmaceuticals, Vaccines, OTC and Performance Enhancers)
|
May 2009 |
£2310 |
14 % |
Business Development: Accelerating the Deal
|
May 2008 |
£5080 |
13.5 % |
OTC Pharmaceuticals in Mexico
|
February 2009 |
£87 |
12.95 % |
Stakeholder Opinions: Restless Legs Syndrome Novel drugs to prosper as lifecycle management strategies fail
|
November 2008 |
£2640 |
12 % |
Rewarding & Recognizing Top-Performing Sales People
|
March 2008 |
£2290 |
12 % |
Managed Markets Account Management
Assessing the Performance of Account Executives
|
October 2009 |
£2780 |
12 % |
Challenges and Changes In a Core Pharmaceutical Function
The Future of Market Research
|
January 2010 |
£2675 |
12 % |
Mapping the e-Pharma Landscape
Who's doing what in Pharma social media
|
February 2010 |
£195 |
11.55 % |
Plk-1 Inhibitors
Competitor Analysis
|
May 2009 |
£90 |
11.55 % |
Pharmaceutical Product Launch Evaluation Excellence
Processes and Measures to Evaluate Launch Success
|
November 2008 |
£2980 |
11.5 % |
Evolving Medical Information Call Centers through Performance Measurement and Process Improvement
|
January 2009 |
£3960 |
11 % |
Best Practices for Post-Marketing Surveillance of Adverse Events within the U.S.
|
September 2009 |
£1910 |
11 % |
Pharma R&D Fact Book, The
2006
|
November 2007 |
£495 |
11 % |
Developing Managed Care Pull-Through Excellence
|
October 2009 |
£3435 |
10.5 % |
World OTC Pharmaceutical Markets
Self-Medication, Developing and Petro-Rich Economies, BTC and Other Growth Trends
|
May 2008 |
£2115 |
10.5 % |
Pharmaceutical Science Exellence
CMC Activities, Resources, and Performance
|
September 2008 |
£6935 |
10.5 % |
Public Relations Excellence: Using PR to Launch, Grow, and Extend Your Brands
|
October 2008 |
£5305 |
10.5 % |
Wound Treatment in Mexico
|
December 2005 |
£450 |
10.15 % |
Chronic Obstructive Pulmonary Disease (COPD)
Drug Pipeline Analysis and Market Forecasts to 2016
|
February 2010 |
£1320 |
10 % |
Smoking Cessation Aids in Mexico
|
December 2005 |
£450 |
9.8 % |
Innovations in Patient-Focused Initiatives
Case Studies in Reaching, Engaging and Supporting Patients
|
July 2009 |
£3020 |
9.5 % |
Brazil Pharmaceuticals and Healthcare Report Q3 2008
|
September 2008 |
£425 |
9.5 % |
Pharmaceutical Parallel Trade in the United Kingdom, 2000-2006
Market Insights and Trends in a Primary Import Destination
|
August 2006 |
£900 |
9.5 % |
Product Lifecycle Management, 2006
|
May 2006 |
£1499 |
9.5 % |
The True State of the Pharmaceutical Industry
|
December 2008 |
£495 |
9.5 % |
UK Vitamins & Mineral Supplements
|
June 2009 |
£600 |
9.45 % |
Medicated Skin Care in Mexico
|
December 2005 |
£450 |
9.45 % |
Protein Kinase C (PKC) Inhibitors
Competitor Analysis
|
January 2009 |
£180 |
9.1 % |
Digestive Remedies in Germany
|
April 2009 |
£560 |
9.1 % |
Eye Care in Germany
|
April 2009 |
£560 |
9.1 % |
Wound Treatments in Germany
|
April 2009 |
£560 |
9.1 % |
Educating the Marketplace to Support Successful Diabetes Product Launches
|
January 2010 |
£5225 |
9 % |
Pharmaceutical Distribution in the US
Current and Future Perspectives
|
July 2009 |
£1495 |
9 % |
Partneringdesk deals and alliances in infectious diseases
|
April 2006 |
£1250 |
9 % |
Wound Treatments in Spain
|
March 2009 |
£560 |
8.75 % |
Analgesics in Netherlands
|
July 2004 |
£450 |
8.75 % |
Big Pharma M&A Analysis to 2012 - Surveying the growth rate landscape
|
August 2008 |
£2510 |
8.75 % |
NRT Smoking Cessation Aids in Germany
|
April 2009 |
£560 |
8.75 % |
Eye Care in Spain
|
March 2009 |
£560 |
8.75 % |
Analgesics in Germany
|
April 2009 |
£560 |
8.75 % |
Digestive Remedies in Spain
|
March 2009 |
£560 |
8.75 % |
Analgesics in Spain
|
March 2009 |
£560 |
8.75 % |
Cough, Cold and Allergy (Hayfever) Remedies in Mexico
|
December 2005 |
£450 |
8.75 % |
Eye Care in Netherlands
|
July 2004 |
£450 |
8.75 % |
Partneringdesk deals and alliances in autoimmune & inflammatory diseases
|
April 2006 |
£1250 |
8.5 % |
Medicated Skin Care in Spain
|
March 2009 |
£560 |
8.4 % |
NRT Smoking Cessation Aids in Spain
|
March 2009 |
£560 |
8.4 % |
Cough, Cold And Allergy (Hay Fever) Remedies in Germany
|
April 2009 |
£560 |
8.4 % |
Bigpharma Partnering Agreements
|
March 2008 |
£1195 |
8.4 % |
Vectura Group plc Product Pipeline Analysis
|
May 2008 |
£495 |
8.4 % |
Wound Treatment in Austria
|
December 2005 |
£450 |
8.4 % |
Digestive Remedies in Netherlands
|
July 2004 |
£450 |
8.4 % |
Bigpharma Agreements Handbook
Partnering Agreements
|
September 2008 |
£1195 |
8.4 % |
Abbott Laboratories
Pharmavitae Profile
|
December 2007 |
£1980 |
8.4 % |
Vitamins and Dietary Supplements in Spain
|
March 2009 |
£560 |
8.4 % |
Medicated Skin Care in Germany
|
April 2009 |
£560 |
8.4 % |
Smoking Cessation Aids in Venezuela
|
January 2006 |
£450 |
8.4 % |
Vitamins And Dietary Supplements in Germany
|
August 2007 |
£450 |
8.4 % |
Smoking Cessation Aids in Netherlands
|
July 2004 |
£450 |
8.4 % |
Eye Care in Mexico
|
February 2008 |
£450 |
8.05 % |
Merck KGaA - OTC Healthcare - World
|
January 2008 |
£195 |
8.05 % |
Vitamins and Dietary Supplements in Netherlands
|
July 2004 |
£450 |
8.05 % |
Medicated Skin Care in Venezuela
|
February 2008 |
£450 |
8.05 % |
Eye Care in Denmark
|
May 2006 |
£450 |
8.05 % |
Cough, Cold and Allergy (Hay Fever) Remedies in Spain
|
March 2009 |
£560 |
8.05 % |
Diabetes Market Forecast to 2015
|
January 2010 |
£6600 |
8 % |
Novel Mitotic Kinase Inhibitors
Competitor Analysis
|
May 2009 |
£315 |
7.7 % |
Wound Treatments in Denmark
|
May 2006 |
£450 |
7.7 % |
Cough, Cold and Allergy (Hay Fever) Remedies in Netherlands
|
July 2004 |
£450 |
7.7 % |
China Asthma Drug Market Report
The Chinese Asthma Drug Drug Utilization
|
May 2009 |
£2970 |
7.7 % |
Smoking Cessation Aids in Germany
|
November 2005 |
£450 |
7.7 % |
Wound Treatments in Mexico
|
September 2006 |
£450 |
7.7 % |
Smoking Cessation Aids in France
|
January 2006 |
£450 |
7.7 % |
Analgesics in Mexico
|
February 2008 |
£450 |
7.7 % |
Digestive Remedies in Japan
|
September 2007 |
£450 |
7.7 % |
Digestive Remedies in New Zealand
|
January 2008 |
£450 |
7.7 % |
Trends and Future Directions for the High Performing District Sales Manager
A Comparative View from 2007 and 2009
|
February 2010 |
£4245 |
7.5 % |
Anti-hypertension - Drug Pipeline Analysis and Market Forecasts to 2016
|
February 2010 |
£1320 |
7.35 % |
Vitamins and Dietary Supplements in Denmark
|
May 2006 |
£450 |
7.35 % |
Acute Ischemic Stroke
Drug Pipeline Analysis and Market Forecasts to 2015
|
December 2009 |
£1320 |
7.35 % |
The Global HIV/Aids Market Outlook To 2012
|
July 2007 |
£1495 |
7.35 % |
Competitor Analysis: EGF-R Agonists and Antagonists
|
October 2009 |
£270 |
7.35 % |
Cough, Cold and Allergy (Hayfever) Remedies in Austria
|
December 2005 |
£450 |
7.35 % |
Digestive Remedies in Mexico
|
February 2008 |
£450 |
7.35 % |
Vitamins and Dietary Supplements in Mexico
|
September 2006 |
£450 |
7.35 % |
Parallel Trade
US Lawmakers Allow Imported Prescriptions Drugs
|
June 2007 |
£1499 |
7 % |
Partnering Agreements with Bigpharma
|
February 2010 |
£1395 |
6.65 % |
Bigpharma Dealmaking and Agreements Handbook 2007
Companies, Contacts & Partnering Agreements
|
September 2007 |
£1195 |
6.65 % |
Bigpharma Dealmaking Handbook
Companies & Contacts
|
September 2008 |
£1195 |
6.65 % |
Wound Treatment in the Netherlands
|
December 2005 |
£450 |
6.65 % |
Survey of Private Companies Active in Pain Drug R&D; A
|
January 2006 |
£415 |
6.65 % |
European Animal Health Markets & Opportunities
|
January 2007 |
£895 |
6.65 % |
Cardiovascular Pharmaceutical Market Trends, 2007 to 2010
Key market forecasts and growth opportunities
|
August 2007 |
£895 |
6.65 % |
The Cardiovascular Market Outlook to 2013
Competitive Landscape, Global Market Analysis and Pipeline Analysis
|
January 2009 |
£2025 |
6.5 % |
Partneringreview 2006 - Company Deal Index
Volume 1
|
February 2006 |
£1395 |
6.5 % |
ResMed Inc. Strategic Analysis Profile
|
November 1999 |
£520 |
6.3 % |
Atrial Fibrillation
Drug Pipeline Analysis and Market Forecasts to 2016
|
February 2010 |
£1320 |
6.3 % |
Smoking Cessation Aids in the Netherlands
|
December 2005 |
£450 |
6.3 % |
Scrip R&D Databook 2006
|
January 2006 |
£1295 |
6.3 % |
Mergers and Acquisitions in the Pharmaceuticals Sector, 2009
Critical success factors for competing in a consolidating market
|
April 2009 |
£1955 |
6.3 % |
Mergers and Aquisitions in the Pharmaceuticals Sector, 2009
Critical success factors for competing in a consolidating market
|
April 2009 |
£995 |
6.3 % |
United States Pharmaceuticals and Healthcare Report Q3 2006
|
July 2006 |
£395 |
6 % |
Digestive Remedies in China
|
September 2007 |
£450 |
5.95 % |
The Asian Cardiovascular Market Outlook to 2014
Regional and therapeutic analysis, pipeline impact and growth opportunities
|
March 2009 |
£2025 |
5.95 % |
Pharmaceutical Companies Performance Tables 2005
|
November 2006 |
£295 |
5.95 % |
Medicated Skin Care in the Netherlands
|
December 2005 |
£450 |
5.95 % |
Competitor Analysis VEGF and VEGF-R Agonists and Antagonists
|
September 2009 |
£540 |
5.95 % |
The Pain Market Outlook to 2011
|
June 2006 |
£1495 |
5.95 % |
OTC Pharmaceuticals - Top 5 Emerging Markets Industry Guide
|
September 2009 |
£655 |
5.95 % |
Digestive Remedies in Brazil
|
August 2007 |
£450 |
5.95 % |
Mexico Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
November 2008 |
£1980 |
5.95 % |
Argentina Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
November 2008 |
£1980 |
5.95 % |
Digestive Remedies in Argentina
|
August 2007 |
£450 |
5.6 % |
The Future of Contract Manufacturing
Market Forecasts to 2015
|
December 2009 |
£2310 |
5.6 % |
Cough, Cold and Allergy (Hayfever) Remedies in the Netherlands
|
December 2005 |
£450 |
5.6 % |
Animal Therapeutics and Diagnostics
|
January 2008 |
£3205 |
5.6 % |
The Global OTC Pharmaceutical Market 2009-2024
|
May 2009 |
£1499 |
5.6 % |
Republic of Korea Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
December 2008 |
£1980 |
5.25 % |
Neurodegenerative Disease Drug Market Analysis and Forecasts 2007
|
June 2007 |
£1999 |
5 % |
Biomanufacturing Strategies
Market Drivers, Build-Vs-Buy Decisions And Opportunities In Contract Relationship Management
|
September 2007 |
£1495 |
4.9 % |
The Asthma, COPD & Allergic Rhinitis Market Outlook to 2011
|
June 2006 |
£1495 |
4.9 % |
Animal Pharm's Top Tier Companies
2007 edition
|
January 2007 |
£895 |
4.9 % |
The Future of the Home Healthcare Equipment Market to 2016
Market Forecasts, Competitive Landscape and Pipeline Analysis
|
March 2010 |
£2310 |
4.9 % |
Emerging Diabetes Drugs
Competitor Analysis
|
November 2008 |
£540 |
4.9 % |
Key Players in Pharmaceutical Contract Manufacturing
Market developments, outsourcing hotspots and growth strategies
|
March 2009 |
£2025 |
4.9 % |
OTC Pharmaceuticals
Global Industry Guide
|
February 2008 |
£495 |
4.9 % |
Protease Inhibitors
Innovation Drives Drug Pipeline
|
February 2009 |
£2475 |
4.9 % |
Mexico Pharmaceuticals and Healthcare Report Q3 2008
|
July 2008 |
£425 |
4.9 % |
Argentina Pharmaceuticals and Healthcare Report Q3 2008
|
July 2008 |
£425 |
4.9 % |
Brazil Drug Delivery Devices Investment Opportunities
Analysis and Forecasts to 2015
|
March 2009 |
£1650 |
4.9 % |
Allergan: Pipeline , Products , Performance , Potential
|
February 2008 |
£595 |
4.55 % |
Australia Drug Delivery Devices Investment Opportunities
Analysis and Forecasts to 2015
|
March 2009 |
£1650 |
4.55 % |
Pre-clinical Stage Partnering Agreements in Biopharma
|
October 2008 |
£1195 |
4.55 % |
Germany Pharmaceuticals and Healthcare Report Q2 2009
|
April 2009 |
£250 |
4.55 % |
Alzheimer's and Parkinson's Diseases
A Global Update of Market Trends & Opportunities
|
November 2009 |
£1980 |
4.55 % |
Alzheimer's and Parkinson's Diseases
A Global Update of Market Trends & Opportunities
|
November 2009 |
£1980 |
4.55 % |
Animal Pharm's Top 20
2006 edition
|
January 2006 |
£795 |
4.2 % |
Partneringreview 2006 – Deal Type
Volume 5
|
February 2006 |
£1395 |
4 % |
Partneringreview 2006 – Stage of Development
Volume 4
|
February 2006 |
£1395 |
4 % |
Partneringreview 2006
|
February 2006 |
£2195 |
4 % |
Partneringreview 2006 – Therapy Area
Volume 2
|
February 2006 |
£1395 |
4 % |
Partneringreview 2006 – Financings
Volume 3
|
February 2006 |
£1395 |
4 % |
Partneringreview 2006 – Industry Sector
Volume 6
|
February 2006 |
£1395 |
4 % |
New Drug Futures: Anti-Infective Chapter
|
May 2006 |
£695 |
3.85 % |
Global Cardiovascular Drugs Market 2009-2024
|
June 2009 |
£1499 |
3.85 % |
Amgen
Prospects to 2010
|
February 2009 |
£595 |
3.85 % |
Product and Asset Purchase Agreements in Pharma, Biotech and Diagnostics
|
November 2008 |
£1195 |
3.85 % |
Analyzing the Nutraceuticals Market in the UK
|
January 2009 |
£575 |
3.85 % |
The Global Antivirals Market
R&D Pipelines, Market Analysis and Competitive Landscape
|
May 2007 |
£1650 |
3.85 % |
Distribution Agreements in Pharma, Biotech and Diagnostics
2nd edition
|
March 2010 |
£1495 |
3.5 % |
World Respiratory Disorders Market 2009-2024
|
June 2009 |
£1499 |
3.5 % |
Discovery Stage Partnering Agreements in Biopharma
|
September 2008 |
£1195 |
3.5 % |
Anticoagulants
A Global Market Review
|
November 2009 |
£1980 |
3.5 % |
Licensing Strategies - Examining Todays Pharmaceutical Licensing Trends
|
November 2007 |
£5020 |
3.5 % |
Oncology Partnering Agreements in Pharma, Biotech and Diagnostics
|
June 2009 |
£1195 |
3.5 % |
China Hypertension Drug Market Report
The Chinese Hospital Cancer Drug Utilization
|
February 2009 |
£5285 |
3.5 % |
Animal Health Products Antibacterials Markets
|
May 2008 |
£1320 |
3.5 % |
Pipeline Insight: Asthma/COPD
Targeted therapies on the horizon
|
November 2006 |
£3965 |
3.5 % |
Kinase Therapeutics
Pipeline Assessment and Commercial Prospects
|
January 2010 |
£2995 |
3.5 % |
Non-Small-Cell Lung Cancer (NSCLC)
Drug Pipeline Analysis and Market Forecasts to 2015
|
December 2009 |
£1320 |
3.5 % |
Merger and Acquisition Agreements in Pharma, Biotech and Diagnostics
|
March 2010 |
£1495 |
3.15 % |
Drug Delivery Partnering Agreements In Pharma & Biotech
|
October 2009 |
£1195 |
3.15 % |
Commercial Insight: HIV - The battle for market share is getting fiercer
|
August 2008 |
£5020 |
3.15 % |
Manufacturing & Supply Agreements in Pharma, Biotech and Diagnostics
2nd Edition
|
July 2009 |
£1195 |
3.15 % |
Kinase Inhibitors: Global Markets
|
November 2009 |
£3205 |
3.15 % |
Global Markets for Asthma and COPD Drugs
|
October 2009 |
£3205 |
3.15 % |
Option & Evaluation Agreements in Pharma and Biotech
|
March 2009 |
£995 |
3.15 % |
Generic Benchmarking: Brand Erosion at Patent Expiry
Healthcare
|
March 2009 |
£2640 |
3.15 % |
Psychopharmacotherapy Market Insights
Obstacles & Opportunities in Mood Disorders & Cognitive Impairment, 2005-2012
|
November 2005 |
£795 |
3.15 % |
Scrip Yearbook 2007
23rd Edition (2 Volumes)
|
January 2006 |
£895 |
3.15 % |
Global Market for Sleep-Wake Disorders, 2005-2012, The
Trends, Opportunities, and Insights in a High-Value CNS Therapy Area
|
December 2005 |
£795 |
3.15 % |
Botanical and Plant-Derived Drugs
Global Markets
|
February 2009 |
£3205 |
2.8 % |
Commercial Insight: Asthma & COPD
|
June 2009 |
£10040 |
2.8 % |
United Sates Drug Delivery Devices Investment Opportunities
Analysis and Forecasts to 2015
|
March 2009 |
£1650 |
2.8 % |
Lymphoma Drug Development Strategies at Work
|
June 2009 |
£1745 |
2.8 % |
All Change in the US Pharma Market?
|
June 2008 |
£995 |
2.8 % |
Women's Health: Diagnostic Testing
|
August 2008 |
£1200 |
2.8 % |
The Japanese Pharmaceutical Market Outlook to 2014
Policy environment, market structure, competitive landscape, growth opportunities
|
January 2010 |
£3835 |
2.8 % |
The World OTC Pharmaceutical Market Analysis & Forecasts, 2008-2023
|
June 2008 |
£1499 |
2.8 % |
Clinical Stage Partnering Agreements in Biopharma
|
June 2008 |
£1195 |
2.8 % |
Pfizer Prospects to 2010
Pipeline, Products,Performance,Potential
|
September 2007 |
£595 |
2.8 % |
Co-Promotion & Co-Marketing Agreements in Pharma, Biotech and Diagnostics
|
February 2010 |
£1495 |
2.8 % |
The Future of Respiratory Diseases Therapeutics
Market Forecasts to 2015
|
December 2009 |
£2310 |
2.8 % |
Gastrointestinal Drug Discoveries
|
January 2008 |
£995 |
2.8 % |
Allergy Drugs
|
February 2010 |
£2610 |
2.45 % |
Generic Competition, 2007–11
The impact of patent expiries on sales of major drugs
|
February 2007 |
£1375 |
2.45 % |
Global Market and Future Outlook for Neurodegenerative Disorder Therapies 2007, The
|
January 2007 |
£1485 |
2.45 % |
Anti-Aging Products to 2009
|
June 2005 |
£2775 |
2.45 % |
Partnering Agreements In Diagnostics
Trends in diagnostics partnering deals
|
September 2009 |
£1195 |
2.45 % |
Competitive Outlook on HCV
What to Know & Expect in R&D and Business Development
|
June 2004 |
£895 |
2.45 % |
Early Stage and Discovery Deals
Strategy, Structure and Payment Terms 2nd Edition
|
December 2006 |
£1880 |
2.45 % |
World Nutraceuticals to 2010
|
July 2006 |
£3630 |
2.45 % |
Gastrointestinal Disorders Market Intelligence to 2012
|
May 2007 |
£1499 |
2.45 % |
Strategies and Solutions for Publication Planning and Execution Excellence
|
September 2007 |
£75 |
2.45 % |
Competitive Outlook of Cancer Drug Development
The Missing Handbook to New Product Planning and Portfolio Planning
|
August 2009 |
£2195 |
2.45 % |
CNS Therapeutics
A World Market Review
|
November 2009 |
£1980 |
2.45 % |
Diabetes Drug Pipeline
Competitor Analysis
|
November 2008 |
£1075 |
2.45 % |
World Diabetes Market Analysis 2009-2023
|
February 2009 |
£1499 |
2.45 % |
World Market for Prescription Cardiovascular Drugs
2nd Edition
|
November 2007 |
£2640 |
2.45 % |
ASCO 2009: Significant Developments in Context
|
July 2009 |
£595 |
2.1 % |
The Future of Orphan Diseases Therapeutics
Market Forecasts to 2015
|
December 2009 |
£2310 |
2.1 % |
World Sleep Disorders Market Analysis 2009-2024
|
June 2009 |
£1499 |
2.1 % |
Anti-Hypertensive Drugs
|
February 2010 |
£2610 |
2.1 % |
World Neurodegenerative Diseases Market 2009-2024
|
September 2009 |
£1499 |
2.1 % |
Renal Disease Treatments: Products and Therapies
|
November 2009 |
£3205 |
2.1 % |
China Pharma Outsourcing Annual Review
2009
|
November 2009 |
£915 |
2.1 % |
The Future of Central Nervous System Diseases Therapeutics
Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
|
December 2009 |
£2310 |
2.1 % |
Quality for Biologics
Critical quality attributes, process and change control, product variation, characterisation, and regulatory concerns
|
December 2008 |
£1495 |
2.1 % |
Pharma Marketing ROI
|
January 2007 |
£75 |
2.1 % |
Patient Compliance Europe
|
August 2006 |
£75 |
2.1 % |
Advanced Drug Delivery Systems: New Developments, New Technologies
|
August 2009 |
£3205 |
2.1 % |
Contract Pharmaceutical Manufacturing, Research, and Packaging
|
October 2009 |
£3205 |
2.1 % |
Pipeline Insight: Molecular Targeted Cancer Therapies
More pipeline activity, less product differentiation
|
November 2008 |
£5285 |
2.1 % |
Online Marketing and eDetailing
|
July 2006 |
£75 |
2.1 % |
Drug Safety for Marketed Drugs
|
April 2006 |
£75 |
2.1 % |
Pharmaceutical Contract Manufacturing and Research
|
May 2005 |
£2885 |
2.1 % |
Global Drug Delivery Devices Investment Opportunities
Analysis and Forecasts to 2015
|
March 2009 |
£2640 |
2.1 % |
Pharmaceutical Pricing, Reimbursement and Parallel Trade 2006
|
March 2006 |
£1320 |
2.1 % |
Japanese Pharmaceutical Market 2008-2023, the
|
October 2008 |
£1499 |
2.1 % |
Drug Discovery Technologies
A Global Update of Market Trends & Opportunities
|
November 2009 |
£1980 |
1.75 % |
Pfizer
Market Outlook for a Global Leader, 2008-2013
|
August 2008 |
£1499 |
1.75 % |
Lung Cancer Therapeutics
|
July 2009 |
£2610 |
1.75 % |
Pediatric Drugs: the Worldwide Market
3rd Edition
|
December 2007 |
£2640 |
1.75 % |
Hepatitis C Virus and Therapeutics
A Global Update of Market Trends & Opportunities
|
November 2009 |
£1980 |
1.75 % |
Global Market for Antimicrobials and Antifungals; The
Challenging Resistance to 2016
|
December 2006 |
£1600 |
1.75 % |
Antiageing and Life Enhancement Pharmacotherapeutics
|
January 2006 |
£795 |
1.75 % |
Veterinary Health Markets
|
December 2008 |
£2245 |
1.75 % |
HIV: A Strategic Analysis of Therapeutic and Testing Markets
|
March 2006 |
£2310 |
1.75 % |
Enzyme Inhibitors with Broad Therapeutic Applications
|
June 2006 |
£2885 |
1.75 % |
Bioinformatics Markets
Strategies, Business Models and Trends for the Future
|
March 2009 |
£2245 |
1.75 % |
Commercial Insight: Antithrombotics
Market expands as disease management focuses on prevention
|
October 2007 |
£5020 |
1.75 % |
Global Antivirals Market Analysis & Forecasts 2008-2023
|
September 2008 |
£1499 |
1.75 % |
Pipeline Insight: Benign Prostatic Hyperplasia - Novel therapeutics and reformulations will drive market growth
|
April 2009 |
£3965 |
1.75 % |
Leukemia
A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking
|
April 2009 |
£1745 |
1.75 % |
Stakeholder Opinions: Cystic Fibrosis - A pipeline full of hope
Healthcare
|
March 2009 |
£1320 |
1.75 % |
Oncology Market Leaders
Analyses and Outlook, Market Report 2008 - 2023
|
October 2008 |
£1499 |
1.75 % |
Growth Factors (Blood and Tissue)
A World Report
|
November 2009 |
£1980 |
1.75 % |
World Generics Market, 2008-2013
|
November 2008 |
£1499 |
1.75 % |
Pharmaceutical Outsourcing Opportunities Post-Launch
Contract Manufacturing and Contract Sales and Marketing, 3rd Edition
|
January 2009 |
£2310 |
1.75 % |
Pipeline Insight: Non-Small Cell Lung Cancer
Pipeline set to offer only modest improvements
|
April 2008 |
£3965 |
1.4 % |
Dr. Reddy's Market Outlook, Forecasts and Analysis to 2012
|
April 2007 |
£1499 |
1.4 % |
CNS Drug Discoveries
What the Future Holds
|
November 2006 |
£1995 |
1.4 % |
Monoclonal Antibody Therapeutics 2009-2024
|
August 2009 |
£1499 |
1.4 % |
Parkinson's Disease Market analysis and forecasts
2008-2012, 2017 & 2022
|
January 2008 |
£1499 |
1.4 % |
The Global Pain Therapeutics Market
Market Analysis, R&D Pipelines and Competitive Landscape
|
October 2007 |
£1980 |
1.4 % |
The US Pharmaceutical Market 2009-2024
|
November 2009 |
£1499 |
1.4 % |
China Pharma Outsourcing Market By 2015
|
January 2009 |
£1150 |
1.4 % |
The Outlook for Emerging Central American Pharmaceutical Markets 2009
|
January 2009 |
£795 |
1.4 % |
Generic League
Market Analysis and Forecasts, 2007-2012, 2017 & 2022
|
February 2008 |
£1999 |
0.7 % |
